Weinberger M
Department of Pediatrics, University of Iowa Hospitals, Iowa City.
Pediatrician. 1991;18(4):301-11.
Asthma remains a major cause of morbidity and an occasional cause of mortality in children despite greatly increased knowledge of its pathophysiology and newer improved medications. Management of asthma requires consideration of the two components of airway obstruction, spasm of bronchial smooth muscle and inflammation resulting in mucosal edema and mucous secretions. The pharmacologic alternatives include medications that relax bronchial smooth muscle, prevent the release of mediators that induce bronchospasm and inflammation and anti-inflammatory corticosteroids that can reverse or prevent the inflammatory component of asthma. Therapeutic decisions in asthma also require consideration of the clinical pattern of disease which can be classified as intermittent, seasonal allergic or chronic. Therapeutic strategies for the use of pharmacologic agents include intervention measures for reversal of acute symptoms and maintenance measures to prevent symptoms. While all patients need available intervention measures to reverse acute symptoms when present, only those patients with prolonged periods of symptomatology, i.e. seasonal allergic or chronic, require pharmacologic agent for maintenance therapy. When evaluation identifies environmental factors as clinically important precipitants of asthma, appropriate environmental manipulation offers a potentially useful nonpharmacologic approach to therapy. The use of injections of allergenic extracts in selected patients with appropriate inhalant allergen sensitivity offers an immunologic approach for decreasing symptoms in patients with a predominant inhalant allergic component to their disease. Success in the treatment of asthma requires careful consideration of health care delivery. Available measures, when appropriately delivered to the patients when needed, have been convincingly demonstrated to greatly decrease morbidity.
尽管对哮喘的病理生理学有了更深入的了解,并且有了更新的改良药物,但哮喘仍然是儿童发病的主要原因,偶尔也是儿童死亡的原因。哮喘的管理需要考虑气道阻塞的两个组成部分,即支气管平滑肌痉挛和导致粘膜水肿和粘液分泌的炎症。药物选择包括可舒张支气管平滑肌的药物、阻止诱导支气管痉挛和炎症的介质释放的药物以及可逆转或预防哮喘炎症成分的抗炎皮质类固醇。哮喘的治疗决策还需要考虑疾病的临床模式,可分为间歇性、季节性过敏性或慢性。使用药物的治疗策略包括逆转急性症状的干预措施和预防症状的维持措施。虽然所有患者在出现急性症状时都需要可用的干预措施来逆转症状,但只有那些有长期症状的患者,即季节性过敏性或慢性患者,才需要药物进行维持治疗。当评估确定环境因素是哮喘的重要临床诱发因素时,适当的环境控制提供了一种潜在有用的非药物治疗方法。对有适当吸入性过敏原敏感性的特定患者注射变应原提取物,为减少以吸入性过敏成分为主要疾病成分的患者的症状提供了一种免疫方法。哮喘治疗的成功需要仔细考虑医疗保健的提供。现有措施在需要时适当地提供给患者,已令人信服地证明可大大降低发病率。